Orient Pharma CoROCO:4166 +5.02%56 Interest Coverage is 123.74 as of Dec. 2025, which is 894% above its 10-year median of 12.45. GuruFocus rates ROCO:4166 with a GF Score™ of 56/100 and a GF Value™ of NT$45.09 (Significantly Undervalued). The stock has 2 warning signs investors should review. Among 685 Drug Manufacturers companies, Orient Pharma Co ranks better than 66.72% on this metric.
Interest Coverage is a ratio that determines how easily a company can pay interest expenses on outstanding debt. It is calculated by dividing a company's
Operating Income
by its Interest Expense. Orient Pharma Co's
Operating Income
for the
three
months ended in Dec. 2025 was NT$104 Mil. Orient Pharma Co's Interest Expense for the
three
months ended in Dec. 2025 was NT$-1 Mil.
Orient Pharma Co's interest coverage for the quarter that ended in Dec. 2025 was 123.74.
The higher the ratio, the stronger the company's financial strength is.
The historical rank and industry rank for Orient Pharma Co's Interest Coverage or its related term are showing as below:
ROCO:4166'
s Interest Coverage Range Over the Past 10 Years
Min: 2 Med: 12.45 Max: 33.77
Current: 33.77
ROCO:4166's Interest Coverage is ranked better than 66.72% of 685
companies
in the Drug Manufacturers industry
Industry Median: 12.75
vs ROCO:4166: 33.77
Orient Pharma Co (ROCO:4166) Interest Coverage Explanation
Ben Graham requires that a company has a minimum interest coverage of 5 with the companies he invested. If the interest coverage is less than 2, the company is burdened by debt. Any business slow or recession may drag the company into a situation where it cannot pay the interest on its debt.
Interest Coverage is an important factor when GuruFocus ranks a company's overage Financial Strength .
Orient Pharma Co Interest Coverage Related Terms
Orient Pharma Co Interest Coverage Historical Data
* Premium members only.
The historical data trend for Orient Pharma Co's Interest Coverage can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Note: For Interest Coverage, "No debt" indicates no long-term debt. An indication of "No Debt" does not necessarily mean that the company has no long-term debt obligations; it could be due to missing data in the quarterly or annual report. Use caution when interpreting this information.
ROCO:4166 vs ZTS, UTHR: Interest Coverage Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, Orient Pharma Co's Interest Coverage, along with its competitors' market caps and Interest Coverage data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Orient Pharma Co Interest Coverage vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Orient Pharma Co's Interest Coverage distribution charts can be found below:
* The bar in red indicates where Orient Pharma Co's Interest Coverage falls into.
Interest Coverage is a ratio that determines how easily a company can pay interest expenses on outstanding debt. It is calculated by dividing a company's Operating Income (EBIT) by its Interest Expense:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Orient Pharma Co (ROCO:4166) has a Interest Coverage of 123.74 as of Dec. 2025. Interest Coverage measures a company's capability to pay interest expenses on its debt. View historical data on Orient Pharma Co and its competitors. This is 894% above median its historical median of 12.45. Over the past decade, Orient Pharma Co's Interest Coverage has ranged from 2.00 to 33.77. According to the industry distribution chart, Orient Pharma Co ranks #228 out of 685 companies in the Drug Manufacturers industry, placing it in the top 33.3%.
Is Orient Pharma Co's Interest Coverage too high?
Orient Pharma Co's current Interest Coverage of 123.74 is 894% above median its 10-year median of 12.45. Over the past 10 years, this metric has ranged from a low of 2.00 to a high of 33.77. The Drug Manufacturers industry median Interest Coverage is 12.75. Orient Pharma Co's value of 123.74 is 870.5% above this industry median. Based on the distribution chart, Orient Pharma Co ranks #228 out of 685 companies in the Drug Manufacturers industry, which is above the industry midpoint. Overall, Orient Pharma Co has a GF Score™ of 56/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Orient Pharma Co's Interest Coverage compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, Orient Pharma Co ranks #228 out of 685 companies for Interest Coverage. This puts Orient Pharma Co in the upper half of its industry. The industry median Interest Coverage is 12.75. Orient Pharma Co's value of 123.74 is 870.5% above this benchmark. Historically, Orient Pharma Co's own Interest Coverage has ranged from 2.00 to 33.77 over the past decade. While the company's 10-year median is 12.45 vs. the industry median of 12.75, Orient Pharma Co has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Interest Coverage for a Drug Manufacturers company?
The median Interest Coverage among Drug Manufacturers companies is 12.75, based on 685 companies in the industry. Companies in the top quartile (top 25%) have a Interest Coverage significantly above this median, while those in the bottom quartile fall well below. However, Interest Coverage should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Orient Pharma Co's current Interest Coverage of 123.74 is 870.5% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Interest Coverage mean?
A high Interest Coverage can signal that a stock is expensive relative to its fundamentals. Interest Coverage measures a company's capability to pay interest expenses on its debt. View historical data on Orient Pharma Co and its competitors. For the Drug Manufacturers industry, the median Interest Coverage is 12.75 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Orient Pharma Co's current Interest Coverage is 123.74, which is 894% above median its own 10-year median of 12.45. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Orient Pharma Co stock overvalued right now?
Based on GuruFocus' analysis, Orient Pharma Co (ROCO:4166) is currently considered Significantly Undervalued. The stock's GF Value™ is NT$45.09, compared to a current price of NT$27.20 — trading 39.7% below its estimated fair value. The current Interest Coverage is 123.74, which is 894% above median its 10-year median of 12.45 and 870.5% above the Drug Manufacturers industry median of 12.75. Orient Pharma Co's overall GF Score™ is 56/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Interest Coverage calculated?
Interest Coverage is calculated from a company's financial statements. For Orient Pharma Co (ROCO:4166), the current Interest Coverage is 123.74 as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Orient Pharma Co (ROCO:4166) Overvalued in 2026?
Based on GuruFocus' analysis, Orient Pharma Co stock appears to be undervalued.
The current stock price of NT$27.20 is trading 39.7% below its estimated GF Value™ of NT$45.09.
GuruFocus considers Orient Pharma Co to be Significantly Undervalued.
Key valuation signals for ROCO:4166:
Interest Coverage: 123.74 (894% above median its 10-year median of 12.45)
GF Value™: NT$45.09 vs. price of NT$27.20 (39.7% below fair value)
Industry Position: 870.5% above the Drug Manufacturers median (#228 of 685)
No single metric tells the full story. See the ROCO:4166 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Orient Pharma Co Ltd develops and manufactures pharmaceuticals. The Company mainly engages in the manufacturing, wholesale, and retail of western medicine and medical devices, as well as international trade. The company has two operating segments-Taiwan business segment- mainly engaged in developing the Taiwan pharmaceutical market and conducting related business activities and the other segment is Overseas business segment -mainly engaged in developing potential overseas pharmaceutical markets. Company's products include Cardiovascular drugs and Psychotropic drugs. The Group mainly operates in four regions: Taiwan, the United States, the Philippines, and China generating key revenue from Taiwan.
56GF Score
Get the complete analysis for ROCO:4166
Interest Coverage is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ROCO:4166 has been successfully added to your 
